Search

Displaying results 9871 - 9880 of 10000 in total
  1. Drug

    Leukotriene C4

    go.drugbank.com/drugs/DB08855
    Experimental

    The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produ...

    Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine, L-γ-glutamyl-S-[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl]-L-cysteinylglycineCategories: SRS-A
  2. Drug

    Bamet-UD2

    go.drugbank.com/drugs/DB08857
    Experimental

    Bamet-UD2 is a novel bile acid-platinum derivative.

  3. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    [A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular … events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesProducts: พิทาซอร์ 2, PITALIP(R)
  4. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement

    Synonyms: (R)-crizotinibCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  5. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). … [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ADCETRIS®, ADCETRIS 50 MG IV INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇIN TOZ IÇEREN FLAKON ,FLAKON, 1 ADET
  6. Drug

    Gabapentin enacarbil

    go.drugbank.com/drugs/DB08872
    Approved

    It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).

  7. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. … [L11575] Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation.

    Synonyms: Tiacumicin BCategories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  8. Drug

    Taliglucerase alfa

    go.drugbank.com/drugs/DB08876
    Approved

    Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.

    Synonyms: prGC-DProducts: ELELYSO 200 U İNFÜZYONLUK SOLÜSYON İÇİN LİYOFİLİZE TOZ, 1 ADET
  9. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.

    Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 ML
  10. Drug

    Indolepropionic acid

    go.drugbank.com/drugs/DB02758
    Investigational

    Synonyms: 3-(3-Indole)propionic acid, 3-(3-Indolyl)propanoic acidCategories: Heterocyclic Compounds, 2-Ring